SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (11868)6/2/2004 10:04:02 AM
From: rkrw  Read Replies (1) | Respond to of 52153
 
Zeta, it's a standard "approvable" letter. If the breast mets trial hits statistical significance they can reasonably expect final approval. This isn't a conditional approval ala gleevec. I think this is the best alth could have hoped for.

I found the headline and PR to be perfectly fine and not misleading. It was to the point.



To: zeta1961 who wrote (11868)6/2/2004 10:06:00 AM
From: Biomaven  Read Replies (1) | Respond to of 52153
 
This is an approvable letter - no use of the drug until and unless their new trial pans out. Some drugs with an approvable never make it to market.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News